Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation

Fig. 3

HA-L39X rescue assay using proteasomal and lysosomal inhibitors on transfected differentiated cardiomyocytes. A Immunofluorescence images of modHA-L39X transfected cardiomyocytes after a 5 h treatment with DMSO (first panel), 50 nM bafilomycin (second panel), 100 µM MG-132 (third panel) and negative untransfected control (fourth panel). α-Actinin (violet), HA (green), DAPI blue. Scale bars = 50 µm. BC Western blot from modHA-L39X and modHA-PLN transfected cardiomyocytes after 5 h treatment with DMSO, MG-132 or bafilomycin. HA staining showing specific bands representing PLN monomers at ~ 10 kDa. GAPDH was used as loading control. DE Bar graph illustrating the results from the Western blot experiments n = independent experiments. **P < 0.01

Back to article page